

# SHUKRA

PHARMACEUTICALS LTD.

12<sup>th</sup> February, 2024

To  
The General Manager-Listing  
Corporate Relationship Department  
BSE Limited, Ground Floor,  
P.J. Towers, Dalal Street, Mumbai.

Scrip Code: 524632

Sub: - Outcome of Board Meeting held on Monday, February 12, 2024.  
Ref.: Disclosure under Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Dear Sir/Madam,

With reference to above subject and in compliance with Regulation 33 and 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e., Monday February 12, 2024 at 04:30 p.m. and concluded on 05.30 p.m.: -

1. Considered, adopted and approved Unaudited Financial Results for the third quarter and nine months ended on 31<sup>st</sup> December, 2023 along with the Limited Review Report thereon.  
*(The copies of the aforesaid Financial Results along with the Limited Review Reports thereon are enclosed herewith.)*
2. Reviewed the other business of the company.

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully

For Shukra Pharmaceuticals Limited



**Bhoomiben Patel**  
Director  
(DIN: 08316893)

**CIN : L24231GJ1993PLC019079**



**SHUKRA PHARMACEUTICALS LIMITED**

CIN: L24231GJ1993PLC019079

3rd Floor, Dev House, Opposite WIAA Institute, Judges Bungalow Road, Bodakdev, Ahmedabad - 380 054

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31st DECEMBER, 2023**

		Rs. In Lakhs (Except EPS)					
Sr. No.	Particulars	QUARTER ENDED			NINE MONTH ENDED		Year Ended
		31.12.2023 (Unaudited)	30.09.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)	31.12.2022 (Unaudited)	31.03.2023 (Audited)
1	<b>Income from Operations</b>						
I	Revenue from Operations	1,889.06	2,463.83	230.15	6,368.90	1,258.78	5,883.37
	<b>(a) Net Sales/ Income from Operations</b>	<b>1,889.06</b>	<b>2,463.83</b>	<b>230.15</b>	<b>6,368.90</b>	<b>1,258.78</b>	<b>5,883.37</b>
II	Other Income	56.23	24.25	26.93	143.84	30.59	119.67
	<b>Total Income from Operations (I+II)</b>	<b>1,945.29</b>	<b>2,488.08</b>	<b>257.08</b>	<b>6,512.74</b>	<b>1,289.37</b>	<b>6,003.04</b>
2	<b>Expenses</b>						
	(a) Cost of materials consumed	384.85	479.63	216.02	1,067.11	821.57	1,135.02
	(b) Purchase of Stock-in Trade	342.61	1,093.94	-	3,040.52	-	3,430.02
	(c) Changes in inventories of finished goods, and work-in-progress and stock in trade	(0.00)	194.20	(188.21)	178.62	(243.10)	(33.38)
	(d) Employee Benefit Expenses	135.15	137.10	117.48	406.71	367.89	488.92
	(e) Finance Cost	6.57	6.49	5.00	21.52	20.87	28.08
	(f) Depreciation & Amortisation Expenses	51.17	56.17	45.88	153.28	133.17	183.75
	(g) Other Expenses	72.00	50.17	56.33	179.01	141.22	326.46
	<b>Total Expenses</b>	<b>992.35</b>	<b>2,017.70</b>	<b>252.51</b>	<b>5,046.77</b>	<b>1,241.62</b>	<b>5,558.87</b>
3	<b>Profit / (Loss) before Exceptional and Extra ordinary items</b>	<b>952.94</b>	<b>470.38</b>	<b>4.57</b>	<b>1,465.97</b>	<b>47.75</b>	<b>444.17</b>
4	Exceptional Items	-	-	-	-	-	-
5	<b>Profit / (Loss) before Extra ordinary items and Tax (3-4)</b>	<b>952.94</b>	<b>470.38</b>	<b>4.57</b>	<b>1,465.97</b>	<b>47.75</b>	<b>444.17</b>
6	Extra ordinary items	-	-	-	-	-	-
7	<b>Net Profit / (Loss) from Ordinary Activities before Tax(5-6)</b>	<b>952.94</b>	<b>470.38</b>	<b>4.57</b>	<b>1,465.97</b>	<b>47.75</b>	<b>444.17</b>
8	<b>Tax Expenses</b>						
	I. Current Tax	10.38	-	-	10.38	-	-
	II. Deferred Tax	0.38	(0.78)	1.99	0.24	3.95	2.72
	II. Tax of Earlier Year	0.00	0.23	-	0.23	0.80	0.80
	IV. MAT Credit Entitlement	-	-	-	-	-	-
9	<b>Net Profit / (Loss) for the Period (7-8)</b>	<b>942.18</b>	<b>470.93</b>	<b>2.58</b>	<b>1,455.12</b>	<b>43.00</b>	<b>440.65</b>
10	Other Comprehensive Income ( Net off Tax)						(0.94)
	Remeasurement of defined benefit plans	-	-	-	-	-	-
	Prior Period Adjustments & Expenses	-	-	-	-	-	-
11	<b>Total Comprehensive Income for the period (9+10)</b>	<b>942.18</b>	<b>470.93</b>	<b>2.58</b>	<b>1,455.12</b>	<b>43.00</b>	<b>439.71</b>
12	<b>Paid up Equity Share Capital (F. V. of Re. 10/- Each)</b>	<b>1,094.70</b>	<b>1,086.45</b>	<b>156.57</b>	<b>1,094.70</b>	<b>156.57</b>	<b>391.42</b>
13	Other Equity excluding Revaluation Reserve	10.00	10.00	10.00	10.00	10.00	10.00
14	Earnings per Share (of Re. 10/- each ) :						
	(a) Basic-Rs	8.61	1.47	0.16	13.29	2.75	26.21
	(b) Diluted-Rs	8.61	1.47	0.16	13.29	2.75	26.21



**NOTES:**


1. The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its Meeting held on 12th February, 2024. The statutory auditors have carried out review of the results for the quarter ended December 31, 2023 and have expressed an unqualified audit opinion.
2. The Unaudited Financial Statements are prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 ("Act") read with Companies (Indian Accounting Standards) Rules, 2015 as amended and in the format as prescribed under Regulation 33 of the SEBI (LODR) Regulations, 2015.
3. The Unaudited Financial Results of the Company are available on Company's website and also on the website of BSE Limited, i.e. [www.bseindia.com](http://www.bseindia.com), where the Shares of the Company
4. The figures for the previous period/year have been regrouped /reclassified , wherever necessary.
5. During the quarter ended 31st December, 2023, 2 complaints was received and 2 complaints for last quarter attended and closed.
6. The Company is operating in single segment, so above results are for single segment only.

Date: 12th February, 2024

Place: Ahmedabad

For and on behalf of board of Directors

Shukra Pharmaceuticals Limited



BHOOMI PATEL

Director

DIN: 08316893




**INDEPENDENT AUDITOR'S REVIEW REPORT on Standalone Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

To,  
The Board of Directors,  
**SHUKRA PHARMACEUTICALS LIMITED**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **SHUKRA PHARMACEUTICALS LIMITED** (the "Company"), for the quarter ended December 31, 2023 and year to date from April 01, 2023 to December 31, 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) 34 on 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. Emphasis of Matter - No such thing requires to be mentioned hence our conclusion is not modified in respect of this matter.

Place: Ahmedabad  
Date: 12<sup>th</sup> February, 2024  
UDIN: 24133926BKCJHL5131

For MAAK and Associates  
Chartered Accountants  
FRN: 135024W



**Marmik Shah**  
Partner  
M. No. 133926

